Document Detail


RU486: the French experience.
MedLine Citation:
PMID:  7962459     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RU486 (mifepristone) followed by a prostaglandin (PG) analogue has been marketed in France since April 1990 as a medical alternative to surgery for early pregnancy termination. By law, the drug is used only in the centres approved for voluntary pregnancy termination, and its distribution is strictly controlled. Before being marketed, it was distributed to more than 20,000 women, as part of a training programme for the prescribers. Analysis confirmed an efficacy rate of 95.3%. Failures included incomplete ovular expulsion (2.8%), premature vacuum aspiration (0.7%) and ongoing pregnancy (1.2%). Pelvic pain and malaise were reported as side-effects in 1.6 and 1.2% of the cases respectively. Infectious complications were reported in 0.2% of the cases. Three severe adverse events (one of which was fatal) occurred, including myocardial infarction and ventricular arhythmia, in the hours following PG administration and justify a careful medical monitoring in the centre 3-4 h after administration of PG. For this reason, a trial was undertaken to evaluate the efficacy of an oral form of a PGE1 analogue (misoprostol). When RU486 was followed 36-48 h later by 400 micrograms of misoprostol, the efficacy rate was 96.9%, indicating an efficacy equivalent to that obtained with the other PG analogues. The distribution procedures were adequately followed by the prescribers and by the patients. In summary, RU486 constitutes a safe and efficient medical means of pregnancy termination, provided that the manufacturer's recommendations are properly followed.
Authors:
A Ulmann; L Silvestre
Related Documents :
2976579 - Selective termination of multiple gestations.
3919839 - Sequelae and support after termination of pregnancy for fetal malformation.
25332049 - Recurrent brain tumor with hydrocephalus in pregnancy.
15735159 - Is endomyometrial injury during termination of pregnancy or curettage following miscarr...
5130219 - Outpatient termination of pregnancy.
957359 - Laminaria augmentation of midtrimester pregnancy termination by intramuscular prostagla...
22356759 - Risk factors for blood transfusion in singleton pregnancy deliveries in taiwan.
11982979 - Fetal gastric size in normal and abnormal pregnancies.
892629 - Vacuum splintage of the hand.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  9 Suppl 1     ISSN:  0268-1161     ISO Abbreviation:  Hum. Reprod.     Publication Date:  1994 Jun 
Date Detail:
Created Date:  1994-12-21     Completed Date:  1994-12-21     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  126-30     Citation Subset:  IM; J    
Affiliation:
Centre de Recherches Roussel-Uclaf, Romainville, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abdominal Pain / chemically induced
Abortion, Induced* / statistics & numerical data
Adult
Alprostadil / adverse effects,  analogs & derivatives*
Dinoprostone / adverse effects,  analogs & derivatives*,  contraindications
Female
France
Humans
Hypotension / chemically induced
Mifepristone* / adverse effects,  contraindications
Misoprostol
Myocardial Infarction / chemically induced,  mortality
Pilot Projects
Pregnancy
Uterine Hemorrhage / chemically induced
Chemical
Reg. No./Substance:
363-24-6/Dinoprostone; 59122-46-2/Misoprostol; 60325-46-4/sulprostone; 64318-79-2/gemeprost; 745-65-3/Alprostadil; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of progesterone antagonists in combination with prostaglandin for termination of pregnancy.
Next Document:  The use of progesterone antagonists for cervical ripening and as an adjunct to labour and delivery.